CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
Original article

Abcuro secures $66m to support clinical trial of ulviprubart for IBM

ulviprubartPositive
AI Analysis

Summary

Abcuro closed a $66 million Series D funding round to support clinical development of ulviprubart for inclusion body myositis.

Clinical Trial Data

Importance:6/10
Sentiment:
0.60
Series D fundingulviprubartinclusion body myositisclinical trial
Related Companies

Read the original article

Published by Clinical Trials Arena on August 19, 2026 9:30 AM

Read Original